Novo Nordisk and NanoVation Therapeutics have announced a multi-year partnership to advance the development of novel genetic medicines targeting cardiometabolic and rare diseases. The partnership will combine NanoVation Therapeutics’ long-circulating lipid nanoparticle (lcLNP) technology for RNA delivery to cells outside of the liver with Novo Nordisk’s expertise in cardiometabolic and rare disease R&D and clinical […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!